Organometallics
Article
Calcd for C35H40F3N3O3PtS2: C, 48.49; H, 4.65; N, 4.85. Found: C,
48.47; H, 4.46; N, 4.77.
instead of PMe3, and the reaction mixture was kept at 0 °C at all times.
6c was not isolated, as it begins to form 7a after being synthesized. 1H
NMR (δ, CD2Cl2, 400 MHz, 298 K): 1.98 (3H, d, P(CH3)), 1.91 (3H,
(N-tolyl-ATI)Pt(CH3)2(N3)(SMe2) (5a). A Schlenk flask containing
20 mg (0.035 mmol) of 1a was purged with nitrogen, and dry CH2Cl2
was added to the flask. The solution was cooled to −78 °C, and 7.9 μL
(0.07 mmol, 2 equiv) of MeOTf was syringed in to synthesize 3 in situ.
The flask was warmed to room temperature, and the solvent was
removed under vacuum. A large excess of NaN3 was added to the
Schlenk flask. Dry CH2Cl2 was syringed into the flask and the solution
stirred for 18 h. The solvent was removed under vacuum. The
resulting product was purified via flash column chromatography using
an alumina column with a mobile phase of 100% CH2Cl2 to remove
excess NaN3 and organic byproducts followed by 100% CH3CN. The
CH3CN fraction was collected and reduced to dryness and the residue
triturated with pentanes to yield 12 mg (0.019 mmol, 54%) of pure 5a.
2
3
br s, S(CH3)2), 1.54 (3H, d, Pt(CH3), JPt−H = 61 Hz, JP−H = 8 Hz),
1.23 (3H, br s, S(CH3)2), 0.50 (3H, d, Pt(CH3), 2JPt−H = 62 Hz, 3JP−H
= 8 Hz). 13C NMR (δ, CD2Cl2, 125 MHz, 193 K): 164.7−118.6
(PPh2Me and N-tolyl-ATI arom), 18.8 (S(CH3)2), 16.5 (S(CH3)2),
2
1
13.8 (PtCH3, JP−C = 97 Hz), 7.4 (PPh2(CH3), JP−C = 20 Hz), 4.4
(PtCH3). 31P NMR (δ, CD2Cl2, 162 MHz, 298 K): −23.8 (PPh2Me,
1JPt−P = 877 Hz).
[(N-tolyl-ATI)Pt(CH3)2(P(OMe)3)(SMe2)][OTf] (6d). The same
procedure as for 6a was used to prepare 6d, but P(OMe)3 was used
instead of PMe3; 6d was obtained in 96% yield (29 mg, 0.034 mmol).
1H NMR (δ, CD2Cl2, 400 MHz, 298 K): 3.88 (9H, d, P(OCH3)3,
3
3JP−H = 10 Hz), 2.18 (3H, br s, S(CH3)2, JPt−H = 32 Hz), 1.82 (3H,
IR (CH2Cl2): νN 2038 cm−1. 1H NMR (δ, CD2Cl2, 400 MHz, 298 K):
S(CH3)2, 3JPt−H = 36 Hz), 1.17 (3H, d, PtCH3, 2JPt−H = 57 Hz, 3JP−H
=
3
12 Hz), 0.45 (3H, d, PtCH3, 2JPt−H = 63 Hz, 3JP−H = 9 Hz). 13C NMR
(δ, CD2Cl2, 100 MHz, 298 K): 54.7 (P(OCH32)3, 1JP−C = 12 Hz), 22.5
(S(CH3)2), 18.9 (S(CH3)2), 13.6 (PtCH3, JP−C = 189 Hz), 2.2
1.97 (3H, s, S(CH3)2, 3JPt−H = 31 Hz), 1.88 (3H, s, S(CH3)2, 3JPt−H
=
2
36 Hz), 1.07 (3H, s, PtCH3, JPt−H = 70 Hz), 0.38 (3H, s, PtCH3,
2JPt−H = 62 Hz). 13C NMR (δ, CD2Cl2, 100 MHz, 298 K): 19.8
(S(CH3)2), 18.0 (S(CH3)2), 3.4 (PtCH3), −4.33 (PtCH3). A
satisfactory elemental analysis was not obtained; therefore, the purity
1
(PtCH3, JPt−C = 536 Hz). 31P NMR (δ, CD2Cl2, 162 MHz, 298 K):
1
83.2 (P(OMe)3, JPt−P = 1963 Hz).
1
(N-tolyl-ATI)Pt(CH3)(PPh2Me) (7a). Compound 6c was formed
from 20 mg (0.035 mmol) of 1a by the procedure detailed above and
was stirred at room temperature for 4 days and converted completely
to 7a. The reaction mixture can be heated to increase the rate of
conversion, and 6c will completely convert to 7a in 2 days if heated to
40 °C in CH2Cl2. The resulting product was purified via flash column
chromatography using an alumina column with a mobile phase of
100% CH2Cl2, which was collected, reduced to dryness, and triturated
with pentanes to yield pure 7a as a yellow powder in 88% yield (22
mg, 0.031 mmol). X-ray-quality crystals were formed by slow
evaporation of a solution of 7a in methylene chloride at room
temperature. 1H NMR (δ, CD2Cl2, 500 MHz, 298 K): 7.41−6.13
(23H, PPh2CH3 and N-tolyl-ATI arom), 1.04 (3H, d, PPh2(CH3),
2JP−H = 10 Hz), −0.035 (3H, d, PtCH3, 2JPt−H = 69 Hz, 3JP−H = 5 Hz).
13C NMR (δ, CD2Cl2, 125 MHz, 298 K): 166.8−114.7 (PPh2(CH3)
was determined by H NMR.
(N-tolyl-ATI)Pt(CH3)2(CN)(SMe2) (5b). The same procedure as for
5a was used to prepare 5b, but NaCN was used instead of NaN3 to
give 5.8 mg of the product (0.096 mmol, 27.3%). IR (CH2Cl2): νCN
1
2301 cm−1. H NMR (δ, CD2Cl2, 500 MHz, 298 K): 2.23 (3H, s,
S(CH3)2, 3JPt−H = 35 Hz), 1.97 (3H, s, S(CH3)2, 3JPt−H = 35 Hz), 0.69
2
2
(3H, s, PtCH3, JPt−H = 56 Hz), 0.39 (3H, s, PtCH3, JPt−H = 64 Hz).
13C NMR (δ, CD2Cl2, 125 MHz, 298 K): 24.5 (S(CH3)2), 19.1
(S(CH3)2), 3.3 (PtCH3, JPt−C = 367 Hz), 0.0 (PtCH3, JPt−C = 442
Hz). Anal. Calcd for C26H31N3PtS: C, 50.97; H, 5.10; N, 6.86. Found:
C, 51.19; H, 4.89; N, 6.71.
1
1
[(N-tolyl-ATI)Pt(CH3)2(PMe3)(SMe2)][OTf] (6a). In the glovebox,
in a preweighed vial containing 20 mg (0.035 mmol) of 1a was added
CH2Cl2. MeOTf (4.6 μL, 0.042 mmol, 1.2 equiv) was syringed in to
synthesize 3 in situ. The mixture was allowed to react for 5 min, the
solvent was removed under vacuum, and the residue was triturated
with hexanes and dried to remove any excess MeOTf. The residue was
dissolved in CH2Cl2, and 4.3 μL (0.042 mmol, 1.2 equiv) of PMe3 was
syringed into the vial to form a red solution. The solution was allowed
to react for 5 min, and the solvent and excess PMe3 were removed
under vacuum followed by trituration with hexanes to give 6a in 99%
yield (28 mg, 0.035 mmol). X-ray-quality crystals were formed by
recrystallization from layering hexanes on top of a solution of 6a in
1
and N-tolyl-ATI arom), 12.1 (PPh2(CH3), JP−C = 39 Hz), −10.1
2
(PtCH3, JP−C = 10). 31P NMR (δ, CD2Cl2, 162 MHz, 298 K): 1.6
1
(PPh2(CH3), JPt−P = 3979 Hz).
(N-tolyl-ATI)Pt(CH3)(PPh3) (7b). An NMR tube containing 7.6
mg (0.013 mmol) of 1a was purged with nitrogen, and dry CH2Cl2
was syringed into the NMR tube. The solution was cooled to −78 °C,
and 3 μL (0.026 mmol, 2 equiv) of MeOTf was syringed into the
NMR tube to synthesize 3 in situ. The reaction mixture was warmed to
room temperature, and the solvent was removed under vacuum. A
large excess of PPh3 was added to the NMR tube. Dry CD2Cl2 was
added to form a red solution. The solution was stirred for 2 h. The
resulting product was purified via flash column chromatography using
an alumina column with a mobile phase of 100% CH2Cl2, which was
collected, reduced to dryness, and triturated with pentanes to give pure
1
methylene chloride at −35 °C. H NMR (δ, CD2Cl2, 500 MHz, 298
3
K): 2.23 (3H, br s, S(CH3)2, JPt−H = 35 Hz), 1.58 (9H, d, P(CH3)3,
3H, S(CH3)2), 1.36 (3H, d, PtCH3, 2JPt−H = 57 Hz, 3JP−H = 9 Hz), 0.45
2
3
(3H, d, PtCH3, JPt−H = 62 Hz, JP−H = 8 Hz). 13C NMR (δ, CD2Cl2,
125 MHz, 298 K): 21.6 (S(CH3)2), 18.4 (S(CH3)2), 12.5 (PtCH3,
1JPt−C = 370 Hz, 2JP−C = 103 Hz), 11.2 (P(CH3)3, 1JP−C = 20 Hz), 3.08
1
7b in 95% yield (9.2 mg, 0.033 mmol) as a yellow powder. H NMR
1
(PtCH3, JPt−C = 440 Hz). 31P NMR (δ, CD2Cl2, 162 MHz, 298 K):
(δ, CD2Cl2, 500 MHz, 298 K): 7.49−5.98 (28H, PPh3 and N-tolyl-ATI
−30.0 (PMe3, 1JPt−P = 1101 Hz). Anal. Calcd for C29H40F3N2O3PPtS2:
C, 42.91; H, 4.97; N, 3.45. Found: C, 42.88; H, 4.73; N, 3.42.
[(N-tolyl-ATI)Pt(CH3)2(PPhMe2)(SMe2)][OTf] (6b). The same
procedure as for 6a was used to prepare 6b, but PPhMe2 was used
instead of PMe3; 6b was obtained in 97% yield (30 mg, 0.034 mmol).
1H NMR (δ, CD2Cl2, 500 MHz, 298 K): 7.50−6.04 (18H, Ar, PPhMe2
and N-tolyl-ATI arom), 1.99 (3H, br s, S(CH3)2), 1.90 (3H, d,
2
3
arom), −0.33 (3H, d, Pt(CH3), JPt−H = 69 Hz, JP−H = 5 Hz). 13C
NMR (δ, CD2Cl2, 125 MHz, 298 K): 167.0−117.1 (PPh3 and N-tolyl-
ATI arom), −7.7 (PtCH3, JPt−P = 9 Hz). 31P NMR (δ, CD2Cl2, 162
1
1
MHz, 298 K): 18.8 (PPh3, JPt−P = 4134 Hz).
ASSOCIATED CONTENT
■
2
PtP(CH3)2), 1.77 (3H, d, P(CH3)2), 1.36 (3H, d, PtCH3, JPt−H = 59
S
* Supporting Information
Hz, 3JP−H = 8 Hz), 1.08 (3H, br s, S(CH3)2), 0.46 (3H, d, PtCH3 Eq,
CIF files giving crystallographic data for complexes 1a, 3a, 4a,
6a, and 7a. This material is available free of charge via the
3
2JPt−H = 62 Hz, JP−H = 8 Hz). 13C NMR (δ, CD2Cl2, 125 MHz, 298
K): 166.3−121.2 (PPhMe2 and N-tolyl-ATI arom), 13.5 (PtCH3, 2JP−C
1
= 100 Hz), 10.4 (S(CH3)2), 10.2 (PPh(CH3)2, JP−C = 4 Hz), 10.1
(S(CH3)2), 3.7 (PtCH3). 31P NMR (δ, CD2Cl2, 162 MHz, 298 K):
1
−24.1 (PPhMe2, JPt−P
= 1004 Hz). Anal. Calcd for
AUTHOR INFORMATION
■
C34H42F3N2O3PPtS2: C, 46.73; H, 4.84; N, 3.21. Found: C, 46.41;
Corresponding Author
H, 4.75; N, 3.10.
(N.M.W.).
[(N-tolyl-ATI)Pt(CH3)2(PPh2Me)(SMe2)][OTf] (6c). The same
procedure as for 6a was used to prepare 6c, but PPh2Me was used
1949
dx.doi.org/10.1021/om400034y | Organometallics 2013, 32, 1938−1950